Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
Abstract: Provided herein are methods for forming three-dimensional tissues in vivo. In one embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells. In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells and at least one composition that comprises an extracellular matrix (ECM). In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells, at least one composition that comprises an extracellular matrix (ECM), and at least one other additional components.
Type:
Application
Filed:
September 3, 2013
Publication date:
September 3, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Mohit B. Bhatia, Robert J. Hariri, Wolfgang Hofgartner, Jia-Lun Wang, Qian Ye
Abstract: Provided herein are methods of producing natural killer (NK) cells and NK progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of NK cells and NK progenitor cell populations using a three-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein to an individual having the cancer or viral infection.
Type:
Application
Filed:
August 13, 2013
Publication date:
August 13, 2015
Applicant:
Anthrogenesis Corporation
Inventors:
Eric Law, Lin Kang, Vladimir Jankovic, Xiaokui Zhang, Stewart Abbot, Robert J. Hariri
Abstract: The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.
Abstract: Provided herein are methods of generating tissues and organs in vitro or ex vivo comprising depositing cells and extracellular matrix onto a surface, as well as methods of using such tissues and organs. In one embodiment, the cells and ECM used in accordance with the methods for generating tissues (e.g., three-dimensional tissues) and organs described herein are deposited as part of the same composition. In another embodiment, the cells and ECM used in accordance with the methods for generating tissues (e.g., three-dimensional tissues) and organs described herein are deposited as part of different compositions.
Type:
Application
Filed:
September 3, 2013
Publication date:
August 13, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Mohit B. Bhatia, Robert J. Hariri, Wolfgang Hofgartner, Jia-Lun Wang, Qian Ye
Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
Type:
Grant
Filed:
February 14, 2014
Date of Patent:
July 14, 2015
Assignee:
Anthrogenesis Corporation
Inventors:
James Edinger, Qian Ye, Jai-Lun Wang, Robert J. Hariri
Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
Type:
Application
Filed:
November 21, 2014
Publication date:
July 9, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.
Type:
Application
Filed:
January 16, 2015
Publication date:
July 9, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
Abstract: The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.
Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
Abstract: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
Type:
Application
Filed:
October 22, 2014
Publication date:
May 21, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Casper Paludan, James W. Edinger, Ryhor Harbacheuski, RoseAnn Murray, Robert J. Hariri
Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
Type:
Application
Filed:
November 18, 2014
Publication date:
March 12, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
March 3, 2015
Assignee:
Anthrogenesis Corporation
Inventors:
Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
Abstract: Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of ALS.
Abstract: Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of and compositions comprising, such cells.
Type:
Application
Filed:
July 13, 2012
Publication date:
January 22, 2015
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Aleksandar Francki, Ajai Pal, Robert J. Hariri, Vladimir Jankovic
Abstract: Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.
Type:
Application
Filed:
February 22, 2013
Publication date:
January 15, 2015
Applicant:
Anthrogenesis Corporation
Inventors:
Robert J. Hariri, Mohit B. Bhatia, Qian Ye